Drug or treatment

Naxitamab clinical trials

• 8Clinical trials
• 7Countries

Newest trials

All recruiting trials (8)

• Naxitamab added to standard induction therapy for newly diagnosed high-risk neuroblastoma

  This study tests whether adding Naxitamab and GM-CSF to the standard induction therapy improves outcomes for children and young people with newly diagnosed high-risk neuroblastoma.

  Recruiting Phase 2 Shaare Zedek Medical Center · Jerusalem · NCT07537400

• Prolonged Naxitamab with irinotecan, temozolomide, and sargramostim for relapsed or refractory neuroblastoma

  This trial will test whether giving the immunotherapy Naxitamab more slowly, along with irinotecan, temozolomide, and sargramostim, reduces infusion side effects for people with relapsed or refractory neuroblastoma.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07027748

• Naxitamab plus sacituzumab govitecan for metastatic triple-negative breast cancer

  This trial will test whether combining naxitamab with sacituzumab govitecan helps adults with metastatic triple-negative breast cancer.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07011654

• Combining tipifarnib and naxitimab for treating relapsed neuroblastoma

  This study is testing a new combination of an oral drug called tipifarnib and an intravenous drug called naxitimab to see if it can help children with relapsed neuroblastoma.

  Recruiting at 12 sites Phase 2 Milton S. Hershey Medical Center · Little Rock, Arkansas and 11 other locations · NCT06540963

• Gemcitabine and NK cells with or without Naxitamab for metastatic HER2-negative breast cancer

  This study is testing a new treatment using gemcitabine and special immune cells, with or without naxitamab, to see if it helps people with advanced HER2-negative breast cancer feel better and live longer.

  Recruiting Phase 1/2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06026657

• Evaluating Naxitamab for Treating High-Risk Pediatric Neuroblastoma

  This study is testing a new treatment called naxitamab, alone or with other medicines, to see if it can help children with high-risk neuroblastoma feel better and improve their chances of recovery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06013618

• Evaluating Naxitamab for Refractory Ewing's Sarcoma

  This study is testing if adding Naxitamab to chemotherapy can help people with hard-to-treat Ewing's Sarcoma feel better compared to standard treatment alone.

  Recruiting Phase 2 Institute of Mother and Child, Warsaw, Poland · Warsaw, Mazowian and 1 other locations · NCT05968768

• Naxitamab added to standard chemotherapy for high-risk neuroblastoma

  This study is testing if adding a new treatment called naxitamab to regular chemotherapy can help children with high-risk neuroblastoma do better and live longer.

  Recruiting at 25 sites Phase 2 Milton S. Hershey Medical Center · Birmingham, Alabama and 25 other locations · NCT05489887

Quick answers

How many clinical trials of Naxitamab are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in United States (5 trials), Poland (1 trial), China (1 trial), Brazil (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1/2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →